SCHEMBL1145007

SCHEMBL1145007

Cc1n[nH]c2ncc(C(=O)O)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 2/20 0.41
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 4/20 0.41
HCAR2 Q8TDS4 3/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B10 Q99714 1/20 0.41
P4HA1 P13674 2/20 0.39
P4HTM Q9NXG6 1/20 0.39
BRAF P15056 1/20 0.39
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM6B O15054 1/20 0.37
TET3 O43151 1/20 0.37
KDM4A O75164 1/20 0.37
BBOX1 O75936 1/20 0.37
MAPT P10636 1/20 0.37
KDM5A P29375 1/20 0.37
KDM5C P41229 1/20 0.37
ASPH Q12797 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30692607 1.00 HCAR3 (0.41) HCAR3KDM4EALDH1A1HCAR2ALOX15
SCHEMBL30409389 0.84 ATM (0.46) KDM4EALDH1A1HSD17B10BRAFLMNA
SCHEMBL16929785 0.84 ATM (0.46) KDM4EALDH1A1HSD17B10BRAFLMNA
SCHEMBL25515380 0.83 KDM4E (0.41) KDM4EALDH1A1BRAFLMNAMAPT
SCHEMBL17514127 0.83 BRAF (0.56) BRAF
SCHEMBL30409053 0.83 KDM4E (0.41) KDM4EALDH1A1BRAFLMNAMAPT
SCHEMBL17514144 0.81 KDM4E (0.42) HCAR3KDM4EALDH1A1ALOX15HSD17B10
SCHEMBL28586933 0.80 HCAR2 (0.41) HCAR3KDM4EALDH1A1HCAR2ALOX15
SCHEMBL12821790 0.79 AXL (0.60) MAPK1MAP2K4MAPKAPK3MAPK6DYRK1A
SCHEMBL28939697 0.78 HCAR2 (0.38) HCAR3KDM4EALDH1A1HCAR2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117303993-A Nickel-catalyzed olefin asymmetric hydroarylation method and application 南京大学 2023-12-29 CN claimed
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-10-09 US disclosed
CN-117303993-A Nickel-catalyzed olefin asymmetric hydroarylation method and application 南京大学 2023-12-29 CN disclosed
EP-3183239-B1 INDAZOLES MERCK PATENT GMBH (DE) 2018-09-26 EP disclosed
US-9932340-B2 Substituted indoles ABBVIE INC. (US) 2018-04-03 US disclosed
US-9862717-B2 Indazoles MERCK PATENT GMBH (DE) 2018-01-09 US disclosed
US-9862717-B2 Indazoles MERCK PATENT GMBH (DE) 2018-01-09 US disclosed
US-20170349589-A9 Substituted Indoles ABBVIE INC. (US) 2017-12-07 US disclosed
US-20170267675-A1 INDAZOLES MERCK PATENT GMBH (DE) 2017-09-21 US disclosed
US-20170267675-A1 INDAZOLES MERCK PATENT GMBH (DE) 2017-09-21 US disclosed
WO-2016026549-A1 INDAZOLES MERCK PATENT GMBH (DE) 2016-02-25 WO disclosed
WO-2016026549-A1 INDAZOLES MERCK PATENT GMBH (DE) 2016-02-25 WO disclosed
EP-2297163-B1 Pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER (US) 2015-07-08 EP disclosed
EP-2297163-B1 Pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER (US) 2015-07-08 EP disclosed
US-8318762-B2 Pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2012-11-27 US disclosed
US-8318762-B2 Pyrazolospiroketone acetyl-CoA carboxylase inhibitors PFIZER INC. (US) 2012-11-27 US disclosed
US-20110028390-A1 Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER, INC. (US) 2011-02-03 US disclosed
US-20110028390-A1 Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors PFIZER, INC. (US) 2011-02-03 US disclosed
WO-2011000566-A2 COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NEGATIVE-SENSE SSRNA VIRUS INFECTIONS SAVIRA PHARMACEUTICALS GMBH (AT) 2011-01-06 WO disclosed
WO-2009144554-A1 PYRAZOLOSPIROKETONE ACETYL-C0A CARBOXYLASE INHIBITORS PFIZER, INC. (US) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME NEU1, NEU2, NEU4 HCAR3 492/4885KDM4E 4207/4885ALDH1A1 474/4885
US-20110028390-A1 Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors ACACA, PC, ACACB HCAR3 1337/4885KDM4E 1055/4885ALDH1A1 164/4885
US-20170267675-A1 INDAZOLES MKI67, CCNI, BRCA1 HCAR3 1194/4885KDM4E 2176/4885ALDH1A1 167/4885
US-20170349589-A9 Substituted Indoles SUV39H2, SUV39H1, IDO1 HCAR3 472/4885KDM4E 68/4885ALDH1A1 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.